Fresenius Launches €200M+ Corporate Venture Fund to Tap Early-Stage Healthcare Innovation
Key Insights
Fresenius (search) establishes Fresenius Ventures, a corporate venture capital unit with over €200 million in intended investment volume over the next five years.
The fund targets growth fields adjacent to Fresenius (search)' biopharma, medtech, and care provision platforms, including new modalities, microbiome research, and digital care.
Thomas Michael Thestrup, formerly of Angelini Ventures, has been appointed to lead the new unit, bringing experience from Lundbeck, UCB, and Sunstone Capital.
Fresenius (search), the Germany-based global healthcare group, has established Fresenius Ventures, a corporate venture capital fund with an intended investment volume of more than €200 million (US$228 million) over the next five years. The newly-formed unit aims to provide the company with early access to breakthrough technologies, entrepreneurial talent, and new ideas across the healthcare ecosystem.
The fund will invest from early financing rounds through to the growth stage, targeting fields adjacent to Fresenius (search)' three strategic platforms: biopharma, medtech, and care provision. Potential investment areas include new therapeutic modalities, microbiome research, precision nutrition, and digital care provision solutions.
"Fresenius (search) Ventures is a strategic instrument of #FutureFresenius," said Michael Sen, CEO of Fresenius. "Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent, [which] enables us to strengthen our innovation capabilities within the healthcare ecosystem and tap into adjacent growth fields while consistently strengthening Fresenius."
Leadership and Strategic Rationale
Fresenius (search) has appointed Thomas Michael Thestrup to lead the new unit. Thestrup joins from Angelini Ventures, the corporate venture arm of Italy's Angelini Industries, and brings prior experience in business development and strategy roles at Lundbeck and UCB, as well as life sciences investing at Danish venture firm Sunstone Capital.
The fund combines venture capital with medical, regulatory, and operational expertise, and provides portfolio companies access to Fresenius (search)' clinical, scientific, and academic networks. This structure signals that Fresenius seeks to engage with emerging technologies earlier, potentially creating a new route to partnerships, licensing deals, and acquisitions for young biotechs.
Fresenius (search)' Growing Biopharma Footprint
The launch of Fresenius (search) Ventures comes as the company's biopharma activities continue to expand rapidly. Fresenius Kabi's biopharma division generated €871 million in 2025, representing a 43% increase from the previous year, largely driven by growing sales of Tyenne, its biosimilar version of Roche's autoimmune drug Actemra. By comparison, Fresenius Kabi generated total revenue of €8.6 billion in 2025.
The company's biopharma portfolio spans biosimilar development and commercialization, biologics manufacturing, and CDMO services, with a focus on autoimmune diseases, oncology, hematology, and osteoporosis.
Fresenius (search) has made several strategic moves into biotechnology in recent years. In 2017, it acquired Merck KGaA's biosimilars pipeline for up to €656 million. In 2020, it formed an equally owned joint venture with Bio-Techne (search) and Wilson Wolf to develop scalable manufacturing technologies for cell and gene therapies. In 2022, it paid approximately €495 million upfront for a 55% stake in Spanish biosimilars manufacturer mAbxience (search), adding biologics manufacturing and CDMO capabilities. Earlier this year, it licensed cell-selection technology from German biotech TQ Therapeutics (search) for integration into Fresenius Kabi's cell-processing equipment.
Market Context
The fund adds more than €200 million of potential strategic capital to a challenging European healthcare financing market. Fresenius (search) has not disclosed expected ticket sizes, geographic limits, or how the capital will be divided between sectors.
The initiative also unfolds against a backdrop of trade policy uncertainty for the generics sector. Following U.S. President Donald Trump's proposal of tariffs on generic medicines imported to the U.S., Fresenius (search) has argued it is better protected than many competitors, noting that approximately 90% of group revenue is not exposed to U.S. tariffs and roughly 70% of the medicines it sells in the U.S. are already manufactured domestically. The company employs more than 4,000 people in the U.S. and has invested nearly $1 billion in local manufacturing and logistics infrastructure in recent years, though it acknowledged it would not be immune to the proposed measures.
Founded from a German pharmacy business established in 1912, Fresenius (search) has grown into a healthcare group employing more than 178,000 people and generating €22.9 billion in reported revenue in 2025. Its operations are now concentrated around Fresenius Helios, which operates hospitals in Germany and Spain, and Fresenius Kabi, which sells injectable generic medicines, clinical nutrition products, medical devices, and biopharmaceuticals.